US-based University of Iowa Hospital and Clinics (UIHC) has deployed Covidien’s Nellcor pulse oximetry technology, in a bid to improve patient safety at the hospital.
According to the hospital, oximetry can continuously monitor the oxygen level of a patient’s blood and alerts clinicians if a patient’s oxygen status is compromised.
The pulse oximetry technology is capable of monitoring a wide range of patients, even when signal interference is present.
UIHC senior assistant director Amy O’Deen said: "University of Iowa Hospital and Clinics is committed to changing lives, advancing medicine, and improving access to the highest level of care for the people in our catchment area and beyond."
Covidien is said to be the first company to receive US Food and Drug Administration (FDA) approval for a motion-tolerant bedside pulse oximeter.
Pulse oximeters provide early warning of dangerous respiratory complications, allowing clinicians to detect and address life-threatening events sooner.
The technology offers consistent performance during different challenging conditions such as patient motion, noise and low perfusion.
Covidien respiratory and monitoring solutions vice-president and general manager Matt Anderson said: "It is terrific to partner with institutions that are as forward looking and as committed to quality and patient safety as University of Iowa Hospital and Clinics."
UIHC is a 711-bed public teaching hospital and level 1 trauma centre affiliated with the University of Iowa.
It is part of University of Iowa Health Care, a partnership that includes University of Iowa Roy J. and Lucille A. Carver College of Medicine and the University of Iowa Physicians group practice.